ADAPY — Adaptimmune Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual balance sheet for Adaptimmune Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	368	370	205	147	152
Net Total Accounts Receivable
Net Total Receivables	20.7	34	38.1	46.9	16
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	398	415	255	208	188
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	46.7	51.4	71.5	71.7	51.2
Net Intangible Assets
Other Long Term Assets
Total Assets	451	470	329	283	246
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	39.1	62.5	64.5	72.8	64.5
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	110	264	247	243	234
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Unrealized Gain / Loss
Other Equity
Total Equity	341	206	81.9	39.5	11.8
Total Liabilities & Shareholders' Equity	451	470	329	283	246
Total Common Shares Outstanding